Industry Verticals »

All Categories

Insights »

About TMR »

Opioid Tolerance Treatment Market

Opioid Tolerance Treatment Market (Drug - NMDA Antagonists (Ketamine, Dextromethorphan, Others), Alpha2-Adrenoceptor Agonists (Clonidine, Tizanidine, and Others); Type of Opioid Tolerance - Innate Tolerance, Acquired Tolerance; Route of Administration - Enteral, Parenteral; End use - Hospitals and Ambulatory Surgery Centers, Rehabilitation Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Global Opioid Tolerance Treatment – Overview:

Opioid treatment is massively noted in severe pain management and chronic cancer treatment. One of the reasons behind their extensive use is high efficacy. However, there are negative implication sometimes noted when these are used for a longer time. The effect in therapy reduces, and response to therapy becomes dull. Such patients require either higher doses or NMDA antagonists. Alpha2-adrenoceptor agonists are also put to work sometimes.

As per a comprehensive analysis by Transparency Market Research, the market for opioid tolerance treatment will record moderate growth in the market, expanding the opportunities landscape for market players. Valuation of the market would also see growth in the period 2019 to 2027 – the assessment period of the growth.

Some of the prominent factors leading to growth in the market are outlined below. These are molding the future of the market in a major way.

  • Drug abuse is gaining a firm foothold across countries and communities. Some of the regions that are facing a menace in terms of opium use are the countries falling in proximity to the Golden Crescent and the Golden Triangle – regions known for illicit opium production in the Asia Pacific region. Authorities and medical community is trying to fight this through research and development, and development of better therapeutics, paving way for growth in the market.
  • A robust pipeline exists in the market for tolerance treatment and a number of clinical trials are underway. This ensures growth for the global opioid tolerance treatment market over the forecast period. The use in healthcare will be a major factor of growth.

Global Opioid Tolerance Treatment Market - Snapshot

Opioids are effective analgesics prescribed to people with chronic cancer and severe pain. These opioids are generally used for short period of time. If these opioids are prescribed or taken for a longer period of time or more frequent daily doses, they create opioid tolerance in patients and hence, analgesia or desired therapeutic response is not received. In such conditions, higher doses of opioids are required to treating patients.

Opioid tolerant patients can be treated with other treatment options for opioid tolerance such as NMDA antagonists and alpha2-adrenoceptor agonists. These drugs provide the required therapeutic response to opioid tolerant patients or to treat opioid tolerance.

  • The global opioid tolerance treatment market was valued at around US $1,500 Mn in 2018. It is anticipated to expand at a CAGR of around 3.5% from 2019 to 2027. The alpha2-adrenoceptor agonists segment dominates the global opioid tolerance treatment market in terms of value and is expected to continue this trend during the forecast period.
  • The opioid tolerance treatment market is expanding at a significant pace due to rise in consumption of opioids for medical & non-medical purposes and rise in number of opioid prescriptions for therapeutic purpose, which leads opioid tolerance if taken for a long duration of time.
  • Additionally, ongoing clinical trials, various researches going on for opioid tolerant treatment by different research institutes & companies and growing drug abuse, drug overdose cases are some of the major factors responsible for the growth of opioid tolerance treatment market. 

The opioid tolerance treatment market has been segmented based on drug, type of opioid tolerance, route of administration, end-user, and region.

  • On the basis of drug, the global opioid tolerance treatment market has been divided into NMDA antagonists, alpha2-adrenoceptor agonists, and others.
  • The NMDA antagonists segment has been sub-segmented into ketamine, dextromethorphan, and others. The alpha2-adrenoceptor agonists segment is sub-divided into clonidine, tizanidine, and others.
  • The alpha2-adrenoceptor agonists segment dominated the global opioid tolerance treatment market during the forecast period and is expected to continue this trend during the forecast period owing to relatively fewer side effects and better efficacy to treat opioid tolerance.
  • Based on type of opioid tolerance, the global opioid tolerance treatment market has been bifurcated into innate tolerance and acquired tolerance. The acquired tolerance segment dominated the global opioid tolerance treatment market in 2018. The segment is anticipated to expand at a considerable CAGR during the forecast period owing to increase of drug dose & quantity and long term use of opioids.
  • In terms of route of administration, the global opioid tolerance treatment market has been categorized into enteral, parenteral, and others. The parenteral segment dominated the global opioid tolerance treatment market. Faster onset of action and high bioavailability are some factors driving this segment.
  • Based on end-user, the global opioid tolerance treatment market has been classified into hospitals & ASCs, rehabilitation centers, and others. The hospitals & ASCs segment dominated the global opioid tolerance treatment market due to higher number of patient admissions for cancer, chronic pain and better facilities available at these settings. 
opioid tolerance treatment market

In terms of region, the global opioid tolerance treatment market has been split into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

  • North America dominated the global opioid tolerance treatment market in 2018 due to higher number of opioid prescriptions dispensed, high opioid consumptions, and well-established health care infrastructure in the region.
  • The opioid tolerance treatment market in Asia Pacific is expanding at a considerable CAGR during the forecast period due to large cancer patient pool, increase in health care expenditure, and high opioid consumption in the region. 

Key players operating in the global opioid tolerance treatment market include

  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Otsuka Pharmaceutical Co. Ltd.
  • Johnson & Johnson Services
  • Aurobindo Pharma
  • Pfizer Inc.
  • Acorda Therapeutics, Inc.
  • Zydus Cadila

The global opioid tolerance treatment market has been segmented as follows:

Drug
  • NMDA Antagonists
    • Ketamine
    • Dextromethorphan
    • Others (including Guaifenisin)
  • Alpha2-adrenoceptor Agonists
    • Clonidine
    • Tizanidne
    • Others(including Lofexidine)
  • Others (including Endothelin Receptor Antagonists, NSAIDs, Opioid Combinations, and Multimodal Pain Management Drugs)

Opioid Tolerance
  • Innate Tolerance
  • Acquired Tolerance

Route of Administration
  • Enteral
  • Parenteral
  • Others (including Transdermal Route, Patches, and Cartons of Patches) 

End-user
  • Hospitals & ASCs
  • Rehabilitation Centers
  • Others (including Home Care Settings and Research Institutes) 

Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the total market worth of opioid tolerance treatment market?

Opioid tolerance treatment market shall reach to the value of US$ 2 bn by the end of 2027

What is the anticipated CAGR of the opioid tolerance treatment market in the forecast period?

Opioid tolerance treatment market is anticipated to expand at a CAGR of around 3.5% from 2019 to 2027

What are the key driving factors for the growth of the opioid tolerance treatment market?

Opioid tolerance treatment market is driven by rise in consumption of opioids for medical & non-medical purposes and rise in number of opioid prescriptions for therapeutic purpose

Which region is expected to project the highest market share in the global opioid tolerance treatment market?

North America accounted for a major share of the global opioid tolerance treatment market

Who are the key players in the global opioid tolerance treatment market?

Key players operating in the global opioid tolerance treatment market include Boehringer Ingelheim International GmbH, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Otsuka Pharmaceutical Co. Ltd., Johnson & Johnson Services

    1. Preface
          1.1. Market Definition and Scope
          1.2. Market Segmentation
          1.3. Key Research Objectives
          1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Opioid Tolerance Treatment Market

    4. Market Overview
          4.1. Introduction
                  4.1.1. Opioid Tolerance Definition
                  4.1.2. Industry Evolutions / Developments
          4.2. Overview
          4.3. Market Dynamics
                  4.3.1. Drivers
                  4.3.2. Restraints
                  4.3.3. Opportunities
          4.4. Global Opioid Tolerance Treatment Market Analysis and Forecasts, 2017–2027
                  4.4.1. Market Revenue Projections (US$ Mn)
          4.5. Porter’s Five Force Analysis

    5. Market Outlook
          5.1.Key Mergers & Acquisitions 
          5.2.Pipeline Analysis
          5.3.Opioids Side Effects-an Overview
          5.4.Overview of Opioid Tolerance and Epidemiology

    6. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Drug 
          6.1. Introduction & Definition
          6.2. Key Findings / Developments
          6.3. Market Value Forecast, by Drug, 2017–2027
                  6.3.1. NMDA Antagonists
                            6.3.1.1. Ketamine
                            6.3.1.2. Dextromethorphan
                            6.3.1.3. Others
                  6.3.2. Alpha2-adrenoceptor Agonists
                            6.3.2.1. Clonidine
                            6.3.2.2. Tizanidine
                            6.3.2.3. Others
                  6.3.3. Others
          6.4. Market Attractiveness by Drug 

    7. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Type of Opioid Tolerance 
          7.1. Introduction & Definition
          7.2. Key Findings / Developments
          7.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
                  7.3.1. Innate Tolerance
                  7.3.2. Acquired Tolerance
          7.4. Market Attractiveness, by Type of Opioid Tolerance 

    8. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Route of Administration 
          8.1. Introduction & Definition
          8.2. Key Findings / Developments
          8.3. Market Value Forecast, by Route of Administration, 2017–2027
                  8.3.1. Enteral
                  8.3.2. Parenteral
                  8.3.3. Others
          8.4. Market Attractiveness by Route of Administration 

    9. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by End-user 
          9.1. Introduction & Definition
          9.2. Key Findings / Developments
          9.3. Market Value Forecast, by End-user, 2017–2027
                  9.3.1. Hospitals 
                  9.3.2. Rehabilitation Centers
                  9.3.3. Others
          9.4. Market Attractiveness by End-user 

    10. Global Opioid Tolerance Treatment Market Analysis and Forecasts, by Region
          10.1. Key Findings
          10.2. Market Value Forecast, by Region
                  10.2.1. North America 
                  10.2.2. Europe 
                  10.2.3. Asia Pacific 
                  10.2.4. Latin America 
                  10.2.5. Middle East & Africa 
          10.3. Market Attractiveness by Country/Region

    11. North America Opioid Tolerance Treatment Market Analysis and Forecast
          11.1. Introduction
                  11.1.1. Key Findings
          11.2. Market Value Forecast, by Drug, 2017–2027
                  11.2.1. NMDA Antagonists
                            11.2.1.1. Ketamine
                            11.2.1.2. Dextromethorphan
                            11.2.1.3. Others
                  11.2.2. Alpha2-adrenoceptor Agonists
                            11.2.2.1. Clonidine
                            11.2.2.2. Tizanidine
                            11.2.2.3. Others
                  11.2.3. Others
          11.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
                  11.3.1. Innate Tolerance
                  11.3.2. Acquired Tolerance
          11.4. Market Value Forecast, by Route of Administration, 2017–2027
                  11.4.1. Enteral
                  11.4.2. Parenteral
                  11.4.3. Others
          11.5. Market Value Forecast, by End-user, 2017–2027
                  11.5.1. Hospitals 
                  11.5.2. Rehabilitation Centers
                  11.5.3. Others
          11.6. Market Value Forecast, by Country/Sub-region, 2017–2027
                  11.6.1. U.S.
                  11.6.2. Canada
          11.7. Market Attractiveness Analysis 
                  11.7.1. by Drug 
                  11.7.2. by Type of Opioid Tolerance 
                  11.7.3. by Route of Administration 
                  11.7.4. by End-user 
                  11.7.5. by Country/Sub-region

    12. Europe Opioid Tolerance Treatment Market Analysis and Forecast
          12.1. Introduction
                  12.1.1. Key Findings
          12.2. Market Value Forecast, by Drug, 2017–2027
                  12.2.1. NMDA Antagonists
                            12.2.1.1. Ketamine
                            12.2.1.2. Dextromethorphan
                            12.2.1.3. Others
                  12.2.2. Alpha2-adrenoceptor Agonists
                            12.2.2.1. Clonidine
                            12.2.2.2. Tizanidine
                            12.2.2.3. Others
                  12.2.3. Others
          12.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
                  12.3.1. Innate Tolerance
                  12.3.2. Acquired Tolerance
          12.4. Market Value Forecast, by Route of Administration, 2017–2027
                  12.4.1. Enteral
                                12.4.2. Parenteral
                  12.4.3. Others
          12.5. Market Value Forecast, by End-user, 2017–2027
                  12.5.1. Hospitals 
                  12.5.2. Rehabilitation Centers
                  12.5.3. Others
          12.6.Market Value Forecast, by Country/Sub-region, 2017–2027
                  12.6.1. Germany
                  12.6.2. U.K.
                  12.6.3. France
                  12.6.4. Spain
                  12.6.5. Italy
                  12.6.6. Rest of Europe
          12.7. Market Attractiveness Analysis 
                  12.7.1. by Drug 
                  12.7.2. by Type of Opioid Tolerance 
                  12.7.3. by Route of Administration 
                  12.7.4. by End-user 
                  12.7.5. by Country/Sub-region

    13. Asia Pacific Opioid Tolerance Treatment Market Analysis and Forecast
          13.1. Introduction
                  13.1.1. Key Findings
          13.2. Market Value Forecast, by Drug, 2017–2027
                  13.2.1. NMDA Antagonists
                            13.2.1.1. Ketamine
                            13.2.1.2. Dextromethorphan
                            13.2.1.3. Others
                  13.2.2. Alpha2-adrenoceptor Agonists
                            13.2.2.1. Clonidine
                            13.2.2.2. Tizanidine
                            13.2.2.3. Others
                  13.2.3. Others
          13.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
                  13.3.1. Innate Tolerance
                  13.3.2. Acquired Tolerance
          13.4. Market Value Forecast, by Route of Administration, 2017–2027
                  13.4.1. Enteral
                  13.4.2. Parenteral
                  13.4.3. Others
          13.5. Market Value Forecast, by End-user, 2017–2027
                  13.5.1. Hospitals 
                  13.5.2. Rehabilitation Centers
                  13.5.3. Others
          13.6. Market Value Forecast, by Country/Sub-region, 2017–2027
                  13.6.1. China
                  13.6.2. Japan
                  13.6.3. India
                  13.6.4. Australia & New Zealand
                  13.6.5. Rest of Asia Pacific
          13.7. Market Attractiveness Analysis 
                  13.7.1. by Drug 
                  13.7.2. by Type of Opioid Tolerance 
                  13.7.3. by Route of Administration 
                  13.7.4. by End-user 
                  13.7.5. by Country/Sub-region

    14. Latin America Opioid Tolerance Treatment Market Analysis and Forecast
          14.1. Introduction
                  14.1.1. Key Findings
          14.2. Market Value Forecast, by Drug, 2017–2027
                  14.2.1. NMDA Antagonists
                            14.2.1.1. Ketamine
                            14.2.1.2. Dextromethorphan
                            14.2.1.3. Others
                  14.2.2. Alpha2-adrenoceptor Agonists
                            14.2.2.1. Clonidine
                            14.2.2.2. Tizanidine
                            14.2.2.3. Others
                  14.2.3. Others
          14.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
                  14.3.1. Innate Tolerance
                  14.3.2. Acquired Tolerance
          14.4. Market Value Forecast, by Route of Administration, 2017–2027
                  14.4.1. Enteral
                  14.4.2. Parenteral
                  14.4.3. Others
          14.5. Market Value Forecast, by End-user, 2017–2027
                  14.5.1. Hospitals 
                  14.5.2. Rehabilitation Centers
                  14.5.3. Others
          14.6. Market Value Forecast, by Country/Sub-region, 2017–2027
                  14.6.1. Brazil
                  14.6.2. Mexico
                  14.6.3. Rest of Latin America
          14.7. Market Attractiveness Analysis 
                  14.7.1. by Drug 
                  14.7.2. by Type of Opioid Tolerance 
                  14.7.3. by Route of Administration 
                  14.7.4. by End-user 
                  14.7.5. by Country/Sub-region

    15. Middle East & Africa Opioid Tolerance Treatment Market Analysis and Forecast
          15.1. Introduction
                  15.1.1. Key Findings
          15.2. Market Value Forecast, by Drug, 2017–2027
                  15.2.1. NMDA Antagonists
                            15.2.1.1. Ketamine
                            15.2.1.2. Dextromethorphan
                            15.2.1.3. Others
                  15.2.2. Alpha2-adrenoceptor Agonists
                            15.2.2.1. Clonidine
                            15.2.2.2. Tizanidine
                            15.2.2.3. Others
                  15.2.3. Others
          15.3. Market Value Forecast, by Type of Opioid Tolerance, 2017–2027
                  15.3.1. Innate Tolerance
                  15.3.2. Acquired Tolerance
          15.4. Market Value Forecast, by Route of Administration, 2017–2027
                  15.4.1. Enteral
                  15.4.2. Parenteral
                  15.4.3. Others
          15.5. Market Value Forecast, by End-user, 2017–2027
                  15.5.1. Hospitals 
                  15.5.2. Rehabilitation Centers
                  15.5.3. Others
          15.6. Market Value Forecast, by Country/Sub-region, 2017–2027
                  15.6.1. GCC Countries
                  15.6.2. South Africa
                  15.6.3. Rest of Middle East & Africa
          15.7. Market Attractiveness Analysis 
                  15.7.1. by Drug 
                  15.7.2. by Type of Opioid Tolerance 
                  15.7.3. by Route of Administration 
                  15.7.4. by End-user 
                  15.7.5. by Country/Sub-region

    16. Competition Landscape
          16.1. Market Player – Competition Matrix (by Tier and Size of companies)
          16.2. Competitive Business Strategies
          16.3. Company Profiles
                  16.3.1. Boehringer Ingelheim International GmbH
                  16.3.2. GlaxoSmithKline plc
                  16.3.3. Teva Pharmaceutical Industries Ltd.
                  16.3.4. Mylan N.V.
                  16.3.5. Otsuka Pharmaceutical Co., Ltd.
                  16.3.6. Johnson & Johnson Services, Inc.
                  16.3.7. Aurobindo Pharma
                  16.3.8. Pfizer Inc.
                  16.3.9. ACORDA THERAPEUTICS
                  16.3.10. Zydus Cadil

    List of Tables
    Table 01: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
    Table 02: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
    Table 03: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoreceptor Agonists), 2017–2027
    Table 04: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
    Table 05: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 06: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
    Table 07: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
    Table 08: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
    Table 09: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
    Table 10: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
    Table 11: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoreceptor Agonists), 2017–2027
    Table 12: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
    Table 13: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 14: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
    Table 15: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 16: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
    Table 17: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
    Table 18: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
    Table 19: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
    Table 20: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 21: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
    Table 22: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 23: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
    Table 24: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
    Table 25: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
    Table 26: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
    Table 27: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 28: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
    Table 29: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 30: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
    Table 31: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
    Table 32: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
    Table 33: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
    Table 34: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 35: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
    Table 36: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
    Table 37: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
    Table 38: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (NMDA Antagonists), 2017–2027
    Table 39: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Drug (Alpha2-adrenoceptor Agonists), 2017–2027
    Table 40: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Type of Opioid Tolerance, 2017–2027
    Table 41: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2027
    Table 42: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    List of Figures 
    Figure 01: Global Opioid Tolerance Treatment Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
    Figure 02: Revenue Share, by Drug
    Figure 03: Revenue Share, by Type of Opioid Tolerance
    Figure 04: Revenue Share, by Route of Administration
    Figure 05: Revenue Share, by End-user
    Figure 06: Global Opioid Tolerance Treatment Market Value (US$ Mn) Forecast, 2017–2027
    Figure 07: Global Opioid Tolerance Treatment Market Value Share, by Drug, 2018
    Figure 08: Global Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018
    Figure 09: Global Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018
    Figure 10: Global Opioid Tolerance Treatment Market Value Share, by End-user, 2018
    Figure 11: Global Opioid Tolerance Treatment Market Value Share, by Region, 2018
    Figure 12: Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug, 2018 and 2027
    Figure 13: Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
    Figure 14: Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoreceptor Agonists), 2018 and 2027
    Figure 15: Global Opioid Tolerance Treatment Market Revenue (US$ Mn), by NMDA Antagonists, 2017–2027
    Figure 16: Global Opioid Tolerance Treatment Market Revenue (US$ Mn), by Alpha2-adrenoceptor Agonists, 2017–2027
    Figure 17: Global Opioid Tolerance Treatment Market Revenue (US$ Mn), by Others, 2017–2027
    Figure 18: Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Drug, 2017–2027
    Figure 19: Global Opioid Tolerance Treatment Market Value Share Analysis, by Type of Opioid Tolerance, 2018 and 2027
    Figure 20: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Innate Tolerance, 2017–2027
    Figure 21: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Acquired Tolerance, 2017–2027
    Figure 22: Opioid Tolerance Treatment Market Attractiveness Analysis, by Type of Opioid Tolerance, 2019–2027
    Figure 23: Global Opioid Tolerance Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
    Figure 24: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Enteral, 2017–2027
    Figure 25: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2017–2027
    Figure 26: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
    Figure 27: Opioid Tolerance Treatment Market Attractiveness Analysis, by Route of Administration
    Figure 28: Global Opioid Tolerance Treatment Market Value Share Analysis, by End-user, 2018 and 2027
    Figure 29: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals & ASCs, 2017–2027
    Figure 30: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Rehabilitation Centers, 2017–2027
    Figure 31: Global Opioid Tolerance Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
    Figure 32: Opioid Tolerance Treatment Market Attractiveness Analysis, by End-user
    Figure 33: Global Opioid Tolerance Treatment Market Value Share, by Region, 2018 and 2027
    Figure 34: Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Region, 2019–2027
    Figure 35: North America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
    Figure 36: North America Opioid Tolerance Treatment Market Value Share, by Country, 2018 and 2027
    Figure 37: North America Opioid Tolerance Treatment Market Attractiveness, by Country, 2019–2027
    Figure 38: North America Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
    Figure 39: North America Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
    Figure 40: North America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
    Figure 41: North America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
    Figure 42: North America Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
    Figure 43: North America Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
    Figure 44: North America Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
    Figure 45: North America Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
    Figure 46: North America Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
    Figure 47: North America Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
    Figure 48: Europe Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
    Figure 49: Europe Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
    Figure 50: Europe Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
    Figure 51: Europe Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
    Figure 52: Europe Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
    Figure 53: Europe Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
    Figure 54: Europe Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
    Figure 55: Europe Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
    Figure 56: Europe Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
    Figure 57: Europe Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
    Figure 58: Europe Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
    Figure 59: Europe Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
    Figure 60: Europe Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
    Figure 61: Asia Pacific Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
    Figure 62: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
    Figure 63: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
    Figure 64: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
    Figure 65: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
    Figure 66: Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
    Figure 67: Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
    Figure 68: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
    Figure 69: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
    Figure 70: Asia Pacific Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
    Figure 71: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
    Figure 72: Asia Pacific Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
    Figure 73: Asia Pacific Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
    Figure 74: Latin America Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
    Figure 75: Latin America Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
    Figure 76: Latin America Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
    Figure 77: Latin America Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
    Figure 78: Latin America Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
    Figure 79: Latin America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
    Figure 80: Latin America Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
    Figure 81: Latin America Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
    Figure 82: Latin America Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
    Figure 83: Latin America Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
    Figure 84: Latin America Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
    Figure 85: Latin America Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
    Figure 86: Latin America Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027
    Figure 87: Middle East & Africa Opioid Tolerance Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
    Figure 88: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
    Figure 89: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
    Figure 90: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Drug, 2018 and 2027
    Figure 91: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Drug, 2019–2027
    Figure 92: Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Drug (NMDA Antagonists), 2018 and 2027
    Figure 93: Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Drug (Alpha2-adrenoceptor Agonists), 2018 and 2027
    Figure 94: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Type of Opioid Tolerance, 2018 and 2027
    Figure 95: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Type of Opioid Tolerance, 2019–2027
    Figure 96: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by Route of Administration, 2018 and 2027
    Figure 97: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by Route of Administration, 2019–2027
    Figure 98: Middle East & Africa Opioid Tolerance Treatment Market Value Share, by End-user, 2018 and 2027
    Figure 99: Middle East & Africa Opioid Tolerance Treatment Market Attractiveness, by End-user, 2019–2027

Copyright © Transparency Market Research, Inc. All Rights reserved

Opioid Tolerance Treatment Market

Schedule a Call